SLC7A11 and fibrosarcoma: The term “ferroptosis” was formally proposed in 2012, with mechanistic studies demonstrating erastin’s dual action in HT-1080 fibrosarcoma models: mitochondrial voltage-dependent anion channel (VDAC) modulation and inhibition of the Xc system subunit solute carrier family 7 member 11 (SLC7A11), leading to glutathione depletion and iron-dependent lipid ROS accumulation (Dixon et al., 2012).